High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial | Zendy

Yazdan Yazdanpanah | Zendy; Catherine Fagard | Zendy; Diane Descamps | Zendy; Anne Marie Taburet | Zendy; Céline Colin | Zendy; Bénédicte Roquebert | Zendy; Christine Katlama | Zendy; Gilles Pialoux | Zendy; Christine Jacomet | Zendy; Christophe Piketty | Zendy; Diane Bollens | Zendy; JeanMichel Molina | Zendy; Geneviève Chêne | Zendy

Open Access

High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial

Author(s) -

Yazdan Yazdanpanah,

Catherine Fagard,

Diane Descamps,

Anne Marie Taburet,

Céline Colin,

Bénédicte Roquebert,

Christine Katlama,

Gilles Pialoux,

Christine Jacomet,

Christophe Piketty,

Diane Bollens,

JeanMichel Molina,

Geneviève Chêne

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/630210

Subject(s) - darunavir , etravirine , raltegravir , medicine , ritonavir , enfuvirtide , regimen , reverse transcriptase inhibitor , viral load , virology , gastroenterology , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , gp41 , antigen , epitope

The introduction of 2 or 3 fully active drugs in human immunodeficiency virus (HIV)-infected patients receiving failing antiretroviral therapy is a key determinant of subsequent treatment efficacy. The aim of this study was to assess the safety and efficacy of a regimen containing raltegravir, etravirine, and darunavir/ritonavir for treatment-experienced patients infected with multidrug-resistant HIV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research